# US 2021/0060048 A1 · Compositions for improving joint health

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060048 A1
- Document ID: US20210060048A1
- Status: Published application
- Kind: A1
- Application number: 17/011,838
- Filed: 2020-09-03
- Published: 2021-03-04
- Earliest claimed: 2019-09-03
- Assignees: BioRelief, LLC
- Applicants: BioRelief, LLC
- Inventors: Gary Jeffery Ramey; V.A. Shiva Ayyadurai; Prabhakar Deonikar
- Web page: https://patentgrep.com/patent/US20210060048A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, for example, one or more agents that decrease the concentration of cyclooxygenase-2, decrease the concentration of transient receptor potential cation channel subfamily V member 1, and/or decrease calcitonin gene-related peptide concentration. In some embodiments, a composition as provided herein includes apigenin present in an amount of about 1% to about 5% w/w of the composition; and hesperidin present in an amount of about 90% to about 99% w/w of the composition. Such compositions are useful for decreasing joint pain and/or inflammation.

## Claims

### Claim 1

A method for decreasing joint inflammation in a subject in need thereof comprising administering to the subject a composition comprising two or more agents that decrease the concentration of cyclooxygenase-2 (COX-2).

### Claim 2 (depends on 1)

The method of claim 1, wherein the joint inflammation is associated with one or more of: an injury, ankylosing spondylitis, bursitis, gout, juvenile rheumatoid arthritis, lupus, Lyme disease, osteoarthritis, pseudogout, psoriatic arthritis, rheumatoid arthritis, and tendonitis.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein at least one agent that decreases the concentration of COX-2 also decreases one or more of: prostaglandin E2 (PGE2) concentration; the concentration of reactive oxygen species (ROS); and COX-2 expression.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein at least one agent that decreases the concentration of COX-2 modulates COX-2 synthesis.

### Claim 7

(canceled)

### Claim 8 (depends on 4)

The method of claim 4, wherein at least one agent that decreases the concentration of PGE2 modulates arachidonic acid metabolism.

### Claim 9 (depends on 4)

The method of claim 4, wherein the at least one agent that decreases the concentration of ROS modulates an oxidative stress pathway.

### Claim 10 (depends on 1)

The method of claim 1, wherein the two or more agents that decrease COX-2 concentration comprise:
a flavone; and
a flavanone.

### Claim 11

A method for decreasing joint pain of a subject comprising administering to the subject a composition comprising two or more agents that decrease the concentration of transient receptor potential cation channel subfamily V member 1 (TRPV1); decreases the concentration of calcitonin gene-related peptide (CGRP); or a combination thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the joint pain is associated with one or more of: an injury, adult Still's disease, ankylosing spondylitis, avascular necrosis, bone cancer, bursitis, complex regional pain syndrome, fibromyalgia, gonococcal arthritis, gout, hypothyroidism, juvenile idiopathic arthritis, leukemia, lupus, Lyme disease, osteoarthritis, osteomyelitis, Paget's disease of bone, polymyalgia rheumatic, pseudogout, psoriatic arthritis, reactive arthritis, rheumatic fever, rheumatoid arthritis, rickets, sarcoidosis, septic arthritis, and tendinitis.

### Claim 13

(canceled)

### Claim 14 (depends on 11)

The method of claim 11, wherein at least one agent also modulates PGE2 signaling.

### Claim 15 (depends on 11)

The method of claim 11, wherein the two or more agents that decrease the concentration of TRPV1; decrease the concentration of CGRP; or a combination thereof, comprise:
a flavone; and
a flavanone.

### Claim 16 (depends on 15)

The method of claim 15, wherein the flavanone is a trihydroxyflavanone.

### Claim 17 (depends on 16)

The method of claim 16, wherein the trihydroxyflavanone is selected from the group consisting of: hesperidin, butin, garbanzol, naringenin, pinobanksin, and a combination thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the flavanone is hesperidin.

### Claim 19 (depends on 15)

The method of claim 15, wherein the flavanone is present in an amount of about 30% to about 99% w/w of the composition.

### Claim at position 20

-22. (canceled)

### Claim 23 (depends on 15)

The method of claim 15, wherein the flavone is a trihydroxyflavone.

### Claim 24 (depends on 23)

The method of claim 23, wherein the trihydroxyflavone is selected from the group consisting of: apigenin, baicalein, norwogonin, galangin, and a combination thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the flavone is apigenin.

### Claim 26 (depends on 15)

The method of claim 15, wherein the flavone is present in an amount of about 0.01% to about 50% w/w of the composition.

### Claim at position 25

-30. (canceled)

### Claim 31 (depends on 15)

The method of claim 15, wherein the flavanone is hesperidin and the flavone is apigenin.

### Claim at position 27

-36. (canceled)
